NUMB and neoplasm: Both pharmacological and genetic strategies validate that targeted‐blocking the MUC1–PP2A axis significantly elevates PKCζ activity and phosphorylation of NUMB, ultimately suppressing CSLCs and tumor growth in vitro and in vivo.